Target intelligence / Profile preview

FSHD region gene 2 family member C (FRG2C)

Target
FRG2C
Molecular classification
Protein coding gene, Heterochromatin-associated gene, (Some FRG2 family members function as long noncoding RNAs—lncRNAs—but FRG2C itself is protein coding)
01

Overview

FSHD region gene 2 family member C (FRG2C) encodes a nuclear protein that is part of a family of chromatin-associated genes, some of which function as long noncoding RNAs involved in nuclear architecture and heterochromatin regulation[1][2]. FRG2C is predominantly expressed in fibroblasts, with tissue-specific regulation observed among FRG2 paralogs; its encoded protein is detected in the nucleus, and the gene locus is found on chromosome 3p12.3[1][2][3]. While FRG2 family members have been implicated in chromatin organization, only paralog FRG2A is functionally linked to muscular dystrophy (FSHD), through overexpression in muscle tissue of FSHD patients[2][5]. FRG2C itself is sometimes mutated in rare familial hyperphosphatemic tumoral calcinosis and spondyloarthropathy cases[3][4], but is not considered a therapeutic target, nor does it have established roles in major disease categories, drug interactions, or as a clinical biomarker. Its principal biological function appears to be related to heterochromatin regulation and the maintenance of nuclear architecture[2].

Other names
Protein FRG2-like-2HSA3-FRG2FSHD region gene 2 protein family member CFSHD region gene 2 family, member C-likeFRG2C
02

Biological functions

Nuclear localization; associated with chromatin architecturePotential role in regulation of heterochromatinAssociation with nuclear bodies and chromatin-enrichment, but no direct evidence for involvement in canonical signaling, transport, or metabolic pathways
03

Disease associations

Familial tumoral calcinosis (hyperphosphatemic)Spondyloarthropathy 1No direct association with facioscapulohumeral muscular dystrophy (FSHD), but related paralogs (FRG2A) implicated in FSHD pathophysiologyFRG2C mutations may appear in rare calcinosis cases, with other gene alterations present

Beyond the preview

Go deeper on FSHD region gene 2 family member C (FRG2C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FSHD region gene 2 family member C (FRG2C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call